Related Experiment Videos
Drug development for noncastrate prostate cancer in a changed therapeutic landscape
Min Yuen Teo1, Matthew J O'Shaughnessy2, Sean M McBride3
1Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10065, USA.
Abstract:
The unprecedented progress in the treatment of metastatic castration-resistant prostate cancer is only beginning to be realized in patients with noncastrate disease. This slow progress in part reflects the use of trial objectives focused on time-to-event end points, such as time to metastasis and overall survival, which require long follow-up durations and large sample sizes, and has been further delayed by the use of approved therapies that are effective at the time of progression. Our central hypotheses are that progress can be accelerated, and that outcomes can be improved by shifting trial objectives to response measures occurring early that solely reflect the effects of the treatment. To test these hypotheses, a continuously enrolling multi-arm, multi-stage randomized trial design, analogous to that used in the STAMPEDE trial, has been developed. Eligibility is focused on patients with incurable disease or those with a high risk of death with any form of monotherapy alone. The primary objective is to eliminate all disease using a multimodality treatment strategy. End points include pathological complete response and an undetectable level of serum prostate-specific antigen, with recovery of serum testosterone levels. Both are binary, objective, and provide an early, quantitative indication of efficacy.
Insights
Accelerating prostate cancer treatment progress requires shifting trial goals to early response measures. This strategy aims to improve patient outcomes by focusing on early indicators of treatment effectiveness.
Area of Science:
- Oncology
- Clinical Trial Design
Background:
- Metastatic castration-resistant prostate cancer (mCRPC) treatments show promise, but progress in noncastrate disease lags.
- Current trial objectives (e.g., time to metastasis, overall survival) necessitate long follow-ups and large sample sizes, delaying advancements.
- Approved therapies effective at progression further slow the development of novel treatments.
Purpose of the Study:
- To accelerate progress in noncastrate prostate cancer treatment by shifting trial objectives.
- To improve patient outcomes through early response measures that directly reflect treatment efficacy.
- To test the hypothesis that early, objective response metrics can expedite clinical trial findings.
Main Methods:
- Development of a continuously enrolling multi-arm, multi-stage randomized trial design, similar to the STAMPEDE trial.
- Focus on patient eligibility including those with incurable disease or high risk of death on monotherapy.
- Primary objective: disease elimination via multimodality treatment strategy.
Main Results:
- Early, quantitative efficacy indicators are proposed as primary end points.
- Pathological complete response and undetectable serum prostate-specific antigen (PSA) are key metrics.
- Recovery of serum testosterone levels is also included as an objective measure.
Conclusions:
- Shifting trial objectives to early response measures can accelerate progress in noncastrate prostate cancer research.
- Binary, objective end points like pathological complete response and undetectable PSA offer early indications of treatment efficacy.
- This approach facilitates faster evaluation of novel treatment strategies, potentially improving patient outcomes sooner.